| European Federation of Internal Medicine

European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News

Type: News Feed

Human medicines European public assessment report (EPAR): Abrysvo, respiratory syncytial virus vaccine (bivalent, recombinant), Date of authorisation: 23/08/2023, Revision: 15, Status: Authorised

Submitted by Anonymous (not verified) on 21 July 2026 - 13:00

Human medicines European public assessment report (EPAR): Abrysvo, respiratory syncytial virus vaccine (bivalent, recombinant), Date of authorisation: 23/08/2023, Revision: 15, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Abrysvo, respiratory syncytial virus vaccine (bivalent, recombinant), Date of authorisation: 23/08/2023, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Vfend, voriconazole, Date of authorisation: 19/03/2002, Revision: 59, Status: Authorised

Submitted by Anonymous (not verified) on 21 July 2026 - 9:52

Human medicines European public assessment report (EPAR): Vfend, voriconazole, Date of authorisation: 19/03/2002, Revision: 59, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Vfend, voriconazole, Date of authorisation: 19/03/2002, Revision: 59, Status: Authorised

Human medicines European public assessment report (EPAR): Tolucombi, telmisartan,hydrochlorothiazide, Date of authorisation: 13/03/2013, Revision: 14, Status: Authorised

Submitted by Anonymous (not verified) on 21 July 2026 - 9:32

Human medicines European public assessment report (EPAR): Tolucombi, telmisartan,hydrochlorothiazide, Date of authorisation: 13/03/2013, Revision: 14, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Tolucombi, telmisartan,hydrochlorothiazide, Date of authorisation: 13/03/2013, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Fluenz, influenza vaccine (live attenuated, nasal), Date of authorisation: 03/06/2024, Revision: 8, Status: Authorised

Submitted by Anonymous (not verified) on 21 July 2026 - 9:10

Human medicines European public assessment report (EPAR): Fluenz, influenza vaccine (live attenuated, nasal), Date of authorisation: 03/06/2024, Revision: 8, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Fluenz, influenza vaccine (live attenuated, nasal), Date of authorisation: 03/06/2024, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Jascayd, nerandomilast, Date of authorisation: 15/07/2026, Status: Authorised

Submitted by Anonymous (not verified) on 21 July 2026 - 9:00

Human medicines European public assessment report (EPAR): Jascayd, nerandomilast, Date of authorisation: 15/07/2026, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Jascayd, nerandomilast, Date of authorisation: 15/07/2026, Status: Authorised

Human medicines European public assessment report (EPAR): Enhertu, trastuzumab deruxtecan, Date of authorisation: 18/01/2021, Revision: 22, Status: Authorised

Submitted by Anonymous (not verified) on 20 July 2026 - 16:15

Human medicines European public assessment report (EPAR): Enhertu, trastuzumab deruxtecan, Date of authorisation: 18/01/2021, Revision: 22, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Enhertu, trastuzumab deruxtecan, Date of authorisation: 18/01/2021, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Retacrit, epoetin zeta, Date of authorisation: 18/12/2007, Revision: 35, Status: Authorised

Submitted by Anonymous (not verified) on 20 July 2026 - 16:05

Human medicines European public assessment report (EPAR): Retacrit, epoetin zeta, Date of authorisation: 18/12/2007, Revision: 35, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Retacrit, epoetin zeta, Date of authorisation: 18/12/2007, Revision: 35, Status: Authorised

Human medicines European public assessment report (EPAR): Ogsiveo, nirogacestat, Date of authorisation: 14/08/2025, Revision: 3, Status: Authorised

Submitted by Anonymous (not verified) on 20 July 2026 - 15:45

Human medicines European public assessment report (EPAR): Ogsiveo, nirogacestat, Date of authorisation: 14/08/2025, Revision: 3, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Ogsiveo, nirogacestat, Date of authorisation: 14/08/2025, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Pluvicto, lutetium (177Lu) vipivotide tetraxetan, Date of authorisation: 09/12/2022, Revision: 13, Status: Authorised

Submitted by Anonymous (not verified) on 20 July 2026 - 15:38

Human medicines European public assessment report (EPAR): Pluvicto, lutetium (177Lu) vipivotide tetraxetan, Date of authorisation: 09/12/2022, Revision: 13, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Pluvicto, lutetium (177Lu) vipivotide tetraxetan, Date of authorisation: 09/12/2022, Revision: 13, Status: Authorised

European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Human medicines European public assessment report (EPAR): Abrysvo, respiratory syncytial virus vaccine (bivalent, recombinant), Date of authorisation: 23/08/2023, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Vfend, voriconazole, Date of authorisation: 19/03/2002, Revision: 59, Status: Authorised

Human medicines European public assessment report (EPAR): Tolucombi, telmisartan,hydrochlorothiazide, Date of authorisation: 13/03/2013, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Fluenz, influenza vaccine (live attenuated, nasal), Date of authorisation: 03/06/2024, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Jascayd, nerandomilast, Date of authorisation: 15/07/2026, Status: Authorised

Human medicines European public assessment report (EPAR): Enhertu, trastuzumab deruxtecan, Date of authorisation: 18/01/2021, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Retacrit, epoetin zeta, Date of authorisation: 18/12/2007, Revision: 35, Status: Authorised

Human medicines European public assessment report (EPAR): Ogsiveo, nirogacestat, Date of authorisation: 14/08/2025, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Pluvicto, lutetium (177Lu) vipivotide tetraxetan, Date of authorisation: 09/12/2022, Revision: 13, Status: Authorised

Newsletters

Latest Newsletters

You are here

Newsletters

Latest Newsletters